Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa

Prolocor

Status: Completed

Conditions: NSTEMI; STEMI

Treatments: Diagnostic Test: Prolocor pFCG test

Study type: Observational

Funder types: Industry

Identifiers

NCT05175261

PRL-0001

Details and patient eligibility

About

This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and death. Secondary objectives include: 1) Develop a score that combines clinical characteristics plus platelet expression of FcγRIIa to determine the risk of MI, stroke, and death; and 2) Determine whether platelet expression of FcγRIIa is associated with risk of major bleeding. The primary endpoint is the composite of death, MI and stroke. A secondary endpoint is the incidence of clinically significant bleeding according to the Bleeding Academic Research Consortium (BARC) scale type 2-5. Approximately 800 male and female subjects with confirmed MI [ST-segment elevation MI (STEMI) or non-ST-segment elevation MI (NSTEMI)] will be enrolled before hospital discharge for the index event. Approximately 10 sites in the United States will participate in this study. It is anticipated that it will take approximately 12 months to enroll approximately 800 subjects. The study and subject follow-up will continue until 1) at least 80 ischemic events (MI, stroke, and death) have occurred, and 2) the last subject enrolled has completed 18 months of follow-up.

Enrollment: 764 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Type 1 Myocardial Infarction (STEMI and NSTEMI)

2. Must have ≥ 2 of the following risk factors:

   1. Age ≥ 65
   2. Multi-vessel coronary artery disease (MVD) defined as ≥2 vessels or left main with a stenosis ≥50%
   3. Chronic kidney disease (CKD) defined as estimated glomerular filtration rate (GFR) ˂ 60 mL/min/1.73 m2
   4. Diabetes mellitus (DM)
   5. Prior MI

3. Must agree to participate in the study, to comply with all study procedures and follow-up contact

4. Signed the informed consent form

Exclusion criteria

1. Requirement for treatment with full dose anticoagulant therapy (e.g., for atrial fibrillation)
2. Participation in another trial in which the subject is known to receive or could receive anticoagulant or antiplatelet treatment as part of the trial intervention.
3. Non-cardiovascular conditions that, in the judgment of the investigator, will limit survival to less than 2 years

Trial design